Glecaprevir/Pibrentasvir: First Global Approval View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-09-19

AUTHORS

Yvette N. Lamb

ABSTRACT

A fixed-dose combination tablet of the hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) glecaprevir and the HCV NS5A inhibitor pibrentasvir [glecaprevir/pibrentasvir; MAVIRET™ (EU); MAVYRET™ (USA)] has been developed by AbbVie. Oral glecaprevir/pibrentasvir 300 mg/120 mg (three 100 mg/40 mg tablets) taken once daily has been approved by the EMA for the treatment of all major genotypes (genotypes 1–6) of chronic HCV infection in adults. It has also been approved by the US FDA for the treatment of adult patients with chronic HCV genotype 1–6 infection without cirrhosis and with compensated cirrhosis, and for the treatment of adult patients with HCV genotype 1 infection who previously have been treated with a regimen containing either an HCV NS5A inhibitor or an NS3/4A PI, but not both. This article summarizes the milestones in the development of glecaprevir/pibrentasvir leading to its first global approval in the EU and subsequent approval in the USA for chronic HCV infection. More... »

PAGES

1797-1804

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40265-017-0817-y

DOI

http://dx.doi.org/10.1007/s40265-017-0817-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1091844881

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28929412


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1108", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical Microbiology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aminoisobutyric Acids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiviral Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzimidazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclopropanes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Approval", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Combinations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genotype", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepacivirus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepatitis C, Chronic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lactams, Macrocyclic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leucine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Cirrhosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proline", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrrolidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quinoxalines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sulfonamides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United States", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United States Food and Drug Administration", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Viral Nonstructural Proteins", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Springer, Mairangi Bay, Private Bag 65901, 0754, Auckland, New Zealand", 
          "id": "http://www.grid.ac/institutes/grid.420067.7", 
          "name": [
            "Springer, Mairangi Bay, Private Bag 65901, 0754, Auckland, New Zealand"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lamb", 
        "givenName": "Yvette N.", 
        "id": "sg:person.0671216037.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671216037.99"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2017-09-19", 
    "datePublishedReg": "2017-09-19", 
    "description": "A fixed-dose combination tablet of the hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) glecaprevir and the HCV NS5A inhibitor pibrentasvir [glecaprevir/pibrentasvir; MAVIRET\u2122 (EU); MAVYRET\u2122 (USA)] has been developed by AbbVie. Oral glecaprevir/pibrentasvir 300\u00a0mg/120\u00a0mg (three 100\u00a0mg/40\u00a0mg tablets) taken once daily has been approved by the EMA for the treatment of all major genotypes (genotypes 1\u20136) of chronic HCV infection in adults. It has also been approved by the US FDA for the treatment of adult patients with chronic HCV genotype 1\u20136 infection without cirrhosis and with compensated cirrhosis, and for the treatment of adult patients with HCV genotype 1 infection who previously have been treated with a regimen containing either an HCV NS5A inhibitor or an NS3/4A PI, but not both. This article summarizes the milestones in the development of glecaprevir/pibrentasvir leading to its first global approval in the EU and subsequent approval in the USA for chronic HCV infection.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40265-017-0817-y", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1084788", 
        "issn": [
          "0012-6667", 
          "1179-1950"
        ], 
        "name": "Drugs", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "16", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "77"
      }
    ], 
    "keywords": [
      "chronic HCV infection", 
      "First Global Approval", 
      "HCV infection", 
      "adult patients", 
      "Global Approval", 
      "chronic HCV genotype 1", 
      "HCV genotype 1 infection", 
      "glecaprevir/pibrentasvir", 
      "HCV genotype 1", 
      "genotype 1 infection", 
      "fixed-dose combination tablet", 
      "HCV NS5A inhibitors", 
      "compensated cirrhosis", 
      "genotype 1", 
      "NS5A inhibitors", 
      "combination tablet", 
      "US FDA", 
      "infection", 
      "major genotypes", 
      "pibrentasvir", 
      "cirrhosis", 
      "subsequent approval", 
      "patients", 
      "treatment", 
      "approval", 
      "regimen", 
      "glecaprevir", 
      "AbbVie", 
      "mg/120", 
      "FDA", 
      "adults", 
      "inhibitors", 
      "EMA", 
      "genotypes", 
      "tablets", 
      "milestones", 
      "PI", 
      "development", 
      "USA", 
      "article", 
      "EU"
    ], 
    "name": "Glecaprevir/Pibrentasvir: First Global Approval", 
    "pagination": "1797-1804", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1091844881"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40265-017-0817-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28929412"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40265-017-0817-y", 
      "https://app.dimensions.ai/details/publication/pub.1091844881"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:36", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_737.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40265-017-0817-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40265-017-0817-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40265-017-0817-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40265-017-0817-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40265-017-0817-y'


 

This table displays all metadata directly associated to this object as RDF triples.

182 TRIPLES      20 PREDICATES      85 URIs      77 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40265-017-0817-y schema:about N0ccc25fad99947e7be6bde5b912e8fa8
2 N2c6be295463a48b5b978a277082d04ec
3 N30d3f2dafe084ddaba0cf95b0c638fae
4 N3875def816284501a21a6a555b29c51e
5 N3931b7b3bd2d4aef892d502e4360436c
6 N44d38bb1beb04d00a3df827cfd3730f9
7 N5b56449efb2c4c9e9da9ac433bb383f8
8 N5c77686e42714f599317cfa00dd5ca0c
9 N5df79bfe28484319a6cf6c3f23fceaf5
10 N6d3f26e267414d2fa7dd6b39b1596212
11 N70a5bb3f396d4e78a6901d0cfa8dd7d7
12 N7a095c850bf7434cb1bc90a0ffb28c2a
13 N987430e0fe644b17a7f4755fbbf7cf13
14 N9d373f6581714cbea9c4635059bfa344
15 Na84a9f4052fb403290143fa357e383c8
16 Nbe40fbda2f6e4684944771e789f28598
17 Nd6a992846c14487fb38d5affbd81eba2
18 Ne8f919bb50dc4406aabd404c5aed5095
19 Nf63a33f841184ff0bcdeaa7b6efc7297
20 Nf9e5722b98004a12b3735ede1ab0f9b4
21 anzsrc-for:11
22 anzsrc-for:1108
23 schema:author N5d40ac9d784b46d985e6347b3a032e35
24 schema:datePublished 2017-09-19
25 schema:datePublishedReg 2017-09-19
26 schema:description A fixed-dose combination tablet of the hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) glecaprevir and the HCV NS5A inhibitor pibrentasvir [glecaprevir/pibrentasvir; MAVIRET™ (EU); MAVYRET™ (USA)] has been developed by AbbVie. Oral glecaprevir/pibrentasvir 300 mg/120 mg (three 100 mg/40 mg tablets) taken once daily has been approved by the EMA for the treatment of all major genotypes (genotypes 1–6) of chronic HCV infection in adults. It has also been approved by the US FDA for the treatment of adult patients with chronic HCV genotype 1–6 infection without cirrhosis and with compensated cirrhosis, and for the treatment of adult patients with HCV genotype 1 infection who previously have been treated with a regimen containing either an HCV NS5A inhibitor or an NS3/4A PI, but not both. This article summarizes the milestones in the development of glecaprevir/pibrentasvir leading to its first global approval in the EU and subsequent approval in the USA for chronic HCV infection.
27 schema:genre article
28 schema:isAccessibleForFree false
29 schema:isPartOf N5c241607078d488b87f676c1ac1741bc
30 Ne270bf6a1ca04b95870979f1655f510d
31 sg:journal.1084788
32 schema:keywords AbbVie
33 EMA
34 EU
35 FDA
36 First Global Approval
37 Global Approval
38 HCV NS5A inhibitors
39 HCV genotype 1
40 HCV genotype 1 infection
41 HCV infection
42 NS5A inhibitors
43 PI
44 US FDA
45 USA
46 adult patients
47 adults
48 approval
49 article
50 chronic HCV genotype 1
51 chronic HCV infection
52 cirrhosis
53 combination tablet
54 compensated cirrhosis
55 development
56 fixed-dose combination tablet
57 genotype 1
58 genotype 1 infection
59 genotypes
60 glecaprevir
61 glecaprevir/pibrentasvir
62 infection
63 inhibitors
64 major genotypes
65 mg/120
66 milestones
67 patients
68 pibrentasvir
69 regimen
70 subsequent approval
71 tablets
72 treatment
73 schema:name Glecaprevir/Pibrentasvir: First Global Approval
74 schema:pagination 1797-1804
75 schema:productId N60da97bc9d184870b5b18d08c1bfa8a3
76 Nb52a1fe508f948bd9ecce6817b1a463e
77 Nf1ed603265884de6847b419b962f4528
78 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091844881
79 https://doi.org/10.1007/s40265-017-0817-y
80 schema:sdDatePublished 2022-12-01T06:36
81 schema:sdLicense https://scigraph.springernature.com/explorer/license/
82 schema:sdPublisher N8ee62121f2694d14b4cdd6322e4177bd
83 schema:url https://doi.org/10.1007/s40265-017-0817-y
84 sgo:license sg:explorer/license/
85 sgo:sdDataset articles
86 rdf:type schema:ScholarlyArticle
87 N0ccc25fad99947e7be6bde5b912e8fa8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Leucine
89 rdf:type schema:DefinedTerm
90 N2c6be295463a48b5b978a277082d04ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Genotype
92 rdf:type schema:DefinedTerm
93 N30d3f2dafe084ddaba0cf95b0c638fae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Benzimidazoles
95 rdf:type schema:DefinedTerm
96 N3875def816284501a21a6a555b29c51e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Sulfonamides
98 rdf:type schema:DefinedTerm
99 N3931b7b3bd2d4aef892d502e4360436c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Humans
101 rdf:type schema:DefinedTerm
102 N44d38bb1beb04d00a3df827cfd3730f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Quinoxalines
104 rdf:type schema:DefinedTerm
105 N5b56449efb2c4c9e9da9ac433bb383f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Aminoisobutyric Acids
107 rdf:type schema:DefinedTerm
108 N5c241607078d488b87f676c1ac1741bc schema:volumeNumber 77
109 rdf:type schema:PublicationVolume
110 N5c77686e42714f599317cfa00dd5ca0c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Cyclopropanes
112 rdf:type schema:DefinedTerm
113 N5d40ac9d784b46d985e6347b3a032e35 rdf:first sg:person.0671216037.99
114 rdf:rest rdf:nil
115 N5df79bfe28484319a6cf6c3f23fceaf5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Liver Cirrhosis
117 rdf:type schema:DefinedTerm
118 N60da97bc9d184870b5b18d08c1bfa8a3 schema:name pubmed_id
119 schema:value 28929412
120 rdf:type schema:PropertyValue
121 N6d3f26e267414d2fa7dd6b39b1596212 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Antiviral Agents
123 rdf:type schema:DefinedTerm
124 N70a5bb3f396d4e78a6901d0cfa8dd7d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Hepatitis C, Chronic
126 rdf:type schema:DefinedTerm
127 N7a095c850bf7434cb1bc90a0ffb28c2a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Drug Approval
129 rdf:type schema:DefinedTerm
130 N8ee62121f2694d14b4cdd6322e4177bd schema:name Springer Nature - SN SciGraph project
131 rdf:type schema:Organization
132 N987430e0fe644b17a7f4755fbbf7cf13 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Drug Combinations
134 rdf:type schema:DefinedTerm
135 N9d373f6581714cbea9c4635059bfa344 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Hepacivirus
137 rdf:type schema:DefinedTerm
138 Na84a9f4052fb403290143fa357e383c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name United States
140 rdf:type schema:DefinedTerm
141 Nb52a1fe508f948bd9ecce6817b1a463e schema:name dimensions_id
142 schema:value pub.1091844881
143 rdf:type schema:PropertyValue
144 Nbe40fbda2f6e4684944771e789f28598 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Pyrrolidines
146 rdf:type schema:DefinedTerm
147 Nd6a992846c14487fb38d5affbd81eba2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Proline
149 rdf:type schema:DefinedTerm
150 Ne270bf6a1ca04b95870979f1655f510d schema:issueNumber 16
151 rdf:type schema:PublicationIssue
152 Ne8f919bb50dc4406aabd404c5aed5095 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Lactams, Macrocyclic
154 rdf:type schema:DefinedTerm
155 Nf1ed603265884de6847b419b962f4528 schema:name doi
156 schema:value 10.1007/s40265-017-0817-y
157 rdf:type schema:PropertyValue
158 Nf63a33f841184ff0bcdeaa7b6efc7297 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name United States Food and Drug Administration
160 rdf:type schema:DefinedTerm
161 Nf9e5722b98004a12b3735ede1ab0f9b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Viral Nonstructural Proteins
163 rdf:type schema:DefinedTerm
164 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
165 schema:name Medical and Health Sciences
166 rdf:type schema:DefinedTerm
167 anzsrc-for:1108 schema:inDefinedTermSet anzsrc-for:
168 schema:name Medical Microbiology
169 rdf:type schema:DefinedTerm
170 sg:journal.1084788 schema:issn 0012-6667
171 1179-1950
172 schema:name Drugs
173 schema:publisher Springer Nature
174 rdf:type schema:Periodical
175 sg:person.0671216037.99 schema:affiliation grid-institutes:grid.420067.7
176 schema:familyName Lamb
177 schema:givenName Yvette N.
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671216037.99
179 rdf:type schema:Person
180 grid-institutes:grid.420067.7 schema:alternateName Springer, Mairangi Bay, Private Bag 65901, 0754, Auckland, New Zealand
181 schema:name Springer, Mairangi Bay, Private Bag 65901, 0754, Auckland, New Zealand
182 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...